EC-IC direct bypass revascularization for intracranial atherosclerosis. Insights beyond the COSS trial

Other authors

Institut Català de la Salut

[Santos C, Vazquez S] Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Calvo-Rubio H] Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gandara D, Arikan F] Servei de Neurocirurgia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Recerca en Neurotraumatologia i Neurocirurgia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Lorenzo-Bosquet C] Universitat Autònoma de Barcelona, Barcelona, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rubiera M] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Tomasello A] Servei de Neuroradiologia Intervencionista, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-09-19T09:45:56Z

2025-09-19T09:45:56Z

2025-10



Abstract

Intracranial atherosclerosis; Revascularization; Cerebrovascular hemodynamics


Aterosclerosi intracranial; Revascularització; Hemodinàmica cerebrovascular


Aterosclerosis intracraneal; Revascularización; Hemodinámica cerebrovascular


Purpose Despite the results of the EC-IC Bypass International Trial and the Carotid Occlusion Surgery Study (COSS), high-volume centers continue to treat symptomatic intracranial atherosclerotic patients with bypass revascularization. This study aimed to analyze our data and assess whether patient characteristics and outcomes differ from those in EC-IC Bypass and COSS trials. Methods Patients with intracranial atherosclerotic occlusions treated by EC-IC bypass from January 2012 to June 2022 were included. Inclusion criteria were: (1) intracranial atherosclerotic occlusion >70 %, (2) transient or permanent ischemic events in the affected territory, and (3) impaired cerebrovascular reactivity demonstrated by acetazolamide-challenged SPECT. Results Forty-nine patients were included. Half presented bilateral occlusions, and 53.1 % had hemodynamic symptoms. Most were asymptomatic or had mild strokes preoperatively. Postoperatively, mRS worsened in 34.78 % of patients without hemodynamic symptoms, compared to 15 % of symptomatic patients. No significant differences in NIHSS or mRS were observed between pre- and postoperative evaluations. The 30-day complication rate was 20.4 %, with one procedure-related death. High rates of bypass patency (97.95 %) and SPECT improvement (87.75 %) were achieved. Long-term ipsilateral ischemic stroke rate was 2 %. Conclusion EC-IC bypass remains a viable option in carefully selected patients with symptomatic intracranial stenosis and impaired cerebrovascular reserve. Patient selection based on clinical and functional criteria is essential. Our results contrast with those of the COSS trial, showing lower recurrence of ipsilateral ischemic stroke, neurological stability in most patients, and favorable outcomes in individuals with hemodynamic symptoms and contralateral stenosis.

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

World Neurosurgery: X;28

https://doi.org/10.1016/j.wnsx.2025.100496

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)